53 related articles for article (PubMed ID: 15361207)
1. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.
Westin SN; Ju Z; Broaddus RR; Krakstad C; Li J; Pal N; Lu KH; Coleman RL; Hennessy BT; Klempner SJ; Werner HM; Salvesen HB; Cantley LC; Mills GB; Myers AP
Mol Oncol; 2015 Oct; 9(8):1694-703. PubMed ID: 26045339
[TBL] [Abstract][Full Text] [Related]
2. Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas.
Jamieson A; Vermij L; Kramer CJH; Jobsen JJ; Jürgemlienk-Schulz I; Lutgens L; Mens JW; Haverkort MAD; Slot A; Nout RA; Oosting J; Carlson J; Howitt BE; Ip PPC; Lax SF; McCluggage WG; Singh N; McAlpine JN; Creutzberg CL; Horeweg N; Gilks CB; Bosse T
Clin Cancer Res; 2023 Dec; 29(23):4949-4957. PubMed ID: 37773079
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary metastasis of stage I, low-grade endometrioid carcinoma: two case reports and the literature review.
Wang L; Li Y; Han L
Front Oncol; 2023; 13():1266485. PubMed ID: 37901321
[TBL] [Abstract][Full Text] [Related]
4. Targeted Next-Generation Sequencing Identifies Actionable Targets in Estrogen Receptor Positive and Estrogen Receptor Negative Endometriod Endometrial Cancer.
Suhaimi SS; Ab Mutalib NS; Khor SS; Zain RRM; Syafruddin SE; Abu N; Mohd Dali AZH; Jamal R
Front Pharmacol; 2018; 9():750. PubMed ID: 30057548
[TBL] [Abstract][Full Text] [Related]
5. The ErbB Signaling Network and Its Potential Role in Endometrial Cancer.
Androutsopoulos G; Styliara I; Zarogianni E; Lazurko N; Valasoulis G; Michail G; Adonakis G
Epigenomes; 2023 Oct; 7(4):. PubMed ID: 37873809
[TBL] [Abstract][Full Text] [Related]
6. The DNA Damage Response (DDR) landscape of endometrial cancer defines discrete disease subtypes and reveals therapeutic opportunities.
Zhang X; Joseph S; Wu D; Bowser JL; Vaziri C
bioRxiv; 2023 Nov; ():. PubMed ID: 38045328
[TBL] [Abstract][Full Text] [Related]
7. The DNA Damage Response (DDR) landscape of endometrial cancer defines discrete disease subtypes and reveals therapeutic opportunities.
Zhang X; Joseph S; Wu D; Bowser JL; Vaziri C
NAR Cancer; 2024 Jun; 6(2):zcae015. PubMed ID: 38596432
[TBL] [Abstract][Full Text] [Related]
8. Expression of p53 and PTEN in human primary endometrial carcinomas: Clinicopathological and immunohistochemical analysis and study of their concomitant expression.
Stavropoulos A; Varras M; Vasilakaki T; Varra VK; Tsavari A; Varra FN; Nonni A; Kavantzas N; Lazaris AC
Oncol Lett; 2019 May; 17(5):4575-4589. PubMed ID: 30944646
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA TUG1 promotes endometrial cancer development via inhibiting miR-299 and miR-34a-5p.
Liu L; Chen X; Zhang Y; Hu Y; Shen X; Zhu W
Oncotarget; 2017 May; 8(19):31386-31394. PubMed ID: 28404901
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of glypican 3 in endometrial carcinoma and correlation with prognostic parameters.
Hakim SA; Raboh NM
Int J Clin Exp Pathol; 2015; 8(10):13225-32. PubMed ID: 26722522
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of claudin-4 may be involved in endometrial tumorigenesis.
Pan XY; Li X; Che YC; Li HY; Li X; Zhang Y; Yang X
Oncol Lett; 2013 Apr; 5(4):1422-1426. PubMed ID: 23599806
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of miR-205 in endometrial cancer.
Karaayvaz M; Zhang C; Liang S; Shroyer KR; Ju J
PLoS One; 2012; 7(4):e35158. PubMed ID: 22514717
[TBL] [Abstract][Full Text] [Related]
13. Expression and clinical significance of FAK and Src proteins in human endometrial adenocarcinoma.
Chatzizacharias NA; Giaginis C; Gatzidou E; Tsourouflis G; Sfiniadakis I; Alexandrou P; Theocharis SE
Pathol Oncol Res; 2011 Jun; 17(2):277-85. PubMed ID: 21058027
[TBL] [Abstract][Full Text] [Related]
14. The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas.
Gul AE; Keser SH; Barisik NO; Kandemir NO; Cakir C; Sensu S; Karadayi N
Diagn Pathol; 2010 Feb; 5():13. PubMed ID: 20167054
[TBL] [Abstract][Full Text] [Related]
15. Insights into endometrial serous carcinogenesis and progression.
Fadare O; Zheng W
Int J Clin Exp Pathol; 2009; 2(5):411-32. PubMed ID: 19294001
[TBL] [Abstract][Full Text] [Related]
16. The use of P53, PTEN, and C-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma.
Macwhinnie N; Monaghan H
Int J Gynecol Cancer; 2004; 14(5):938-46. PubMed ID: 15361207
[TBL] [Abstract][Full Text] [Related]
17. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
[TBL] [Abstract][Full Text] [Related]
18. [Immunohistochemical expression of PTEN antigen: a new tool for diagnosis of early endometrial neoplasia].
Taranger-Charpin C; Carpentier S; Dales JP; Garcia S; Djemli A; Andrac L; Lavaut MN; Sferlazzo K; Boubli L
Bull Acad Natl Med; 2004; 188(3):415-27; discussion 427-9. PubMed ID: 15584653
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study.
Daniilidou K; Frangou-Plemenou M; Grammatikakis J; Grigoriou O; Vitoratos N; Kondi-Pafiti A
J BUON; 2013; 18(1):195-201. PubMed ID: 23613406
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
